# Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

> **NCT06932068** · PHASE2 · RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 77 (estimated)

## Conditions studied

- HER2 Negative
- Low PD-L1 Expressing
- Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab (QL1706)
- **DRUG:** Oxallplation
- **DRUG:** Capectitabine Tablets

## Key facts

- **NCT ID:** NCT06932068
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-26
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06932068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06932068, "Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT06932068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*